Public health and international drug policy

Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer

doi:10.1016/S0140-6736(16)00619-X

Public health and international drug policy

Joanne Csete, Adeeba Kamarulzaman, Michel Kazatchkine, Frederick Altice, Marek Balicki, Julia Buxton, Javier Cepeda, Megan Comfort, Eric Goosby, João Goulão, Carl Hart, Thomas Kerr, Alejandro Madrazo Lajous, Stephen Lewis, Natasha Martin, Daniel Mejía, Adriana Camacho, David Mathieson, Isidore Obot, Adeolu OgunrombiSusan Sherman, Jack Stone, Nandini Vallath, Peter Vickerman, Tomáš Zábranský, Chris Beyrer

Research output: Contribution to journal › Review article › peer-review

216 Scopus citations

Original language	English (US)
Pages (from-to)	1427-1480
Number of pages	54
Journal	The Lancet
Volume	387
Issue number	10026
DOIs	https://doi.org/10.1016/S0140-6736(16)00619-X
State	Published - Apr 2 2016

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(16)00619-X

Cite this

Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., Hart, C., Kerr, T., Lajous, A. M., Lewis, S., Martin, N., Mejía, D., Camacho, A., Mathieson, D., Obot, I., ... Beyrer, C. (2016). Public health and international drug policy. The Lancet, 387(10026), 1427-1480. https://doi.org/10.1016/S0140-6736(16)00619-X

Csete, J, Kamarulzaman, A, Kazatchkine, M, Altice, F, Balicki, M, Buxton, J, Cepeda, J, Comfort, M, Goosby, E, Goulão, J, Hart, C, Kerr, T, Lajous, AM, Lewis, S, Martin, N, Mejía, D, Camacho, A, Mathieson, D, Obot, I, Ogunrombi, A, Sherman, S, Stone, J, Vallath, N, Vickerman, P, Zábranský, T & Beyrer, C 2016, 'Public health and international drug policy', The Lancet, vol. 387, no. 10026, pp. 1427-1480. https://doi.org/10.1016/S0140-6736(16)00619-X

@article{153c9d914fb24294ae6d105f608092b6,

title = "Public health and international drug policy",

author = "Joanne Csete and Adeeba Kamarulzaman and Michel Kazatchkine and Frederick Altice and Marek Balicki and Julia Buxton and Javier Cepeda and Megan Comfort and Eric Goosby and Jo{\~a}o Goul{\~a}o and Carl Hart and Thomas Kerr and Lajous, {Alejandro Madrazo} and Stephen Lewis and Natasha Martin and Daniel Mej{\'i}a and Adriana Camacho and David Mathieson and Isidore Obot and Adeolu Ogunrombi and Susan Sherman and Jack Stone and Nandini Vallath and Peter Vickerman and Tom{\'a}{\v s} Z{\'a}bransk{\'y} and Chris Beyrer",

note = "Funding Information: The work of the Commission was partly supported by a grant to the Johns Hopkins Center for Public Health and Human Rights from the Open Society Foundation; the Johns Hopkins University Center for AIDS Research, a programme funded by the US National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID; 1 P30AI094189) that supported CB and SGS the Johns Hopkins Training Program in HIV Epidemiology and Prevention Science (1T32AI102623-01A1) of the NIH/NIAID, which supported JCe and the International AIDS Society, Geneva, Switzerland. AK received funding from the University of Malaya High Impact Research Grant (HIRGA E000001-20001). NM and PV received funding from the US National Institute on Drug Abuse (R01 DA037773-01A1). PV was funded by the Bill & Melinda Gates Foundation-funded HIV modeling consortium and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at the University of Bristol, UK. JS acknowledges funding from the UK Engineering and Physical Sciences Research Council (ESPRC). The views expressed in this Commission are those of the authors and not necessarily those of the US NIH or the UK NHS, NIHR, or Department of Health. We acknowledge the contribution of people who contributed material for text boxes, including Daniel Wolfe, Howard Zucker, Anthony Annucci, Sharon Stancliff e, Malik Burnett, and Holly Catania, and the contribution of unpublished data from Romania by Christina Oprea. Funding Information: In some countries, there is a dearth of data for fundamental elements, such as the extent and nature of drug consumption. Nigeria is doing one of Africa's first population-based surveys of drug use, with support from the European Development Fund. 358 The survey is meant, among other things, to serve as a baseline for measuring progress of the improved services for people who use drugs that are also planned. Elsewhere, respected scholars who have endeavoured to bring the best new research to drug policy decision making have sometimes been attacked for their efforts ( appendix ). Funding Information: The Center for Public Health and Human Rights at Johns Hopkins served as the secretariat for the Johns Hopkins–Lancet Commission on Drug Policy and Health. The work of the Commission was partly supported by a grant to the Johns Hopkins Center for Public Health and Human Rights from the Open Society Foundation ; the Johns Hopkins University Center for AIDS Research , a programme funded by the US National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID; 1 P30AI094189 ) that supported CB and SGS; the Johns Hopkins Training Program in HIV Epidemiology and Prevention Science ( 1T32AI102623-01A1 ) of the NIH/NIAID , which supported JCe; and the International AIDS Society, Geneva, Switzerland . AK received funding from the University of Malaya High Impact Research Grant ( HIRGA E000001-20001 ). NM and PV received funding from the US National Institute on Drug Abuse ( R01 DA037773-01A1 ). PV was funded by the Bill & Melinda Gates Foundation -funded HIV modelling consortium and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at the University of Bristol, UK . JS acknowledges funding from the UK Engineering and Physical Sciences Research Council (ESPRC) . The views expressed in this Commission are those of the authors and not necessarily those of the US NIH or the UK NHS, NIHR, or Department of Health. We acknowledge the contribution of people who contributed material for text boxes, including Daniel Wolfe, Howard Zucker, Anthony Annucci, Sharon Stancliffe, Malik Burnett, and Holly Catania, and the contribution of unpublished data from Romania by Christina Oprea. ",

year = "2016",

month = apr,

day = "2",

doi = "10.1016/S0140-6736(16)00619-X",

language = "English (US)",

volume = "387",

pages = "1427--1480",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10026",

}

TY - JOUR

T1 - Public health and international drug policy

AU - Csete, Joanne

AU - Kamarulzaman, Adeeba

AU - Kazatchkine, Michel

AU - Altice, Frederick

AU - Balicki, Marek

AU - Buxton, Julia

AU - Cepeda, Javier

AU - Comfort, Megan

AU - Goosby, Eric

AU - Goulão, João

AU - Hart, Carl

AU - Kerr, Thomas

AU - Lajous, Alejandro Madrazo

AU - Lewis, Stephen

AU - Martin, Natasha

AU - Mejía, Daniel

AU - Camacho, Adriana

AU - Mathieson, David

AU - Obot, Isidore

AU - Ogunrombi, Adeolu

AU - Sherman, Susan

AU - Stone, Jack

AU - Vallath, Nandini

AU - Vickerman, Peter

AU - Zábranský, Tomáš

AU - Beyrer, Chris

N1 - Funding Information: The work of the Commission was partly supported by a grant to the Johns Hopkins Center for Public Health and Human Rights from the Open Society Foundation; the Johns Hopkins University Center for AIDS Research, a programme funded by the US National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID; 1 P30AI094189) that supported CB and SGS the Johns Hopkins Training Program in HIV Epidemiology and Prevention Science (1T32AI102623-01A1) of the NIH/NIAID, which supported JCe and the International AIDS Society, Geneva, Switzerland. AK received funding from the University of Malaya High Impact Research Grant (HIRGA E000001-20001). NM and PV received funding from the US National Institute on Drug Abuse (R01 DA037773-01A1). PV was funded by the Bill & Melinda Gates Foundation-funded HIV modeling consortium and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at the University of Bristol, UK. JS acknowledges funding from the UK Engineering and Physical Sciences Research Council (ESPRC). The views expressed in this Commission are those of the authors and not necessarily those of the US NIH or the UK NHS, NIHR, or Department of Health. We acknowledge the contribution of people who contributed material for text boxes, including Daniel Wolfe, Howard Zucker, Anthony Annucci, Sharon Stancliff e, Malik Burnett, and Holly Catania, and the contribution of unpublished data from Romania by Christina Oprea. Funding Information: In some countries, there is a dearth of data for fundamental elements, such as the extent and nature of drug consumption. Nigeria is doing one of Africa's first population-based surveys of drug use, with support from the European Development Fund. 358 The survey is meant, among other things, to serve as a baseline for measuring progress of the improved services for people who use drugs that are also planned. Elsewhere, respected scholars who have endeavoured to bring the best new research to drug policy decision making have sometimes been attacked for their efforts ( appendix ). Funding Information: The Center for Public Health and Human Rights at Johns Hopkins served as the secretariat for the Johns Hopkins–Lancet Commission on Drug Policy and Health. The work of the Commission was partly supported by a grant to the Johns Hopkins Center for Public Health and Human Rights from the Open Society Foundation ; the Johns Hopkins University Center for AIDS Research , a programme funded by the US National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID; 1 P30AI094189 ) that supported CB and SGS; the Johns Hopkins Training Program in HIV Epidemiology and Prevention Science ( 1T32AI102623-01A1 ) of the NIH/NIAID , which supported JCe; and the International AIDS Society, Geneva, Switzerland . AK received funding from the University of Malaya High Impact Research Grant ( HIRGA E000001-20001 ). NM and PV received funding from the US National Institute on Drug Abuse ( R01 DA037773-01A1 ). PV was funded by the Bill & Melinda Gates Foundation -funded HIV modelling consortium and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at the University of Bristol, UK . JS acknowledges funding from the UK Engineering and Physical Sciences Research Council (ESPRC) . The views expressed in this Commission are those of the authors and not necessarily those of the US NIH or the UK NHS, NIHR, or Department of Health. We acknowledge the contribution of people who contributed material for text boxes, including Daniel Wolfe, Howard Zucker, Anthony Annucci, Sharon Stancliffe, Malik Burnett, and Holly Catania, and the contribution of unpublished data from Romania by Christina Oprea.

PY - 2016/4/2

Y1 - 2016/4/2

UR - http://www.scopus.com/inward/record.url?scp=84964308685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964308685&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(16)00619-X

DO - 10.1016/S0140-6736(16)00619-X

M3 - Review article

C2 - 27021149

AN - SCOPUS:84964308685

SN - 0140-6736

VL - 387

SP - 1427

EP - 1480

JO - The Lancet

JF - The Lancet

IS - 10026

ER -

Public health and international drug policy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this